Loading
Every dated change on the records linked to Erdheim-Chester disease, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Observation with periodic PET and organ screening.
Vemurafenib (approved 2017) or dabrafenib with trametinib; cobimetinib as an alternative; dose reduction to limit toxicity, treatment continued long term.
Cobimetinib (approved 2022 for histiocytic neoplasms); trametinib as an alternative MEK inhibitor.
Biopsy of an accessible lesion with BRAF V600E testing and broader sequencing; FDG-PET/CT, cardiac and brain MRI, endocrine assessment.
Interferon alfa or pegylated interferon, anakinra, cladribine, methotrexate.